Daiwa Securities Group’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,067
Closed -$753K 1432
2022
Q3
$753K Buy
3,067
+167
+6% +$45.1K 0.01% 708
2022
Q2
$718K Buy
2,900
+39
+1% +$10.5K 0.01% 739
2022
Q1
$948K Buy
2,861
+173
+6% +$53.3K 0.01% 716
2021
Q4
$965K Buy
2,688
+168
+7% +$56.8K 0.01% 717
2021
Q3
$820K Buy
2,520
+49
+2% +$16.6K 0.01% 728
2021
Q2
$771K Sell
2,471
-728
-23% -$223K 0.01% 726
2021
Q1
$1.02M Buy
3,199
+932
+41% +$298K 0.01% 612
2020
Q4
$735K Buy
2,267
+80
+4% +$22.1K 0.01% 657
2020
Q3
$606K Buy
2,187
+61
+3% +$17.6K 0.01% 637
2020
Q2
$309K Hold
2,126
0.01% 667
2020
Q1
$309K Buy
2,126
+150
+8% +$24.9K ﹤0.01% 768
2019
Q4
$337K Hold
1,976
﹤0.01% 812
2019
Q3
$352K Buy
1,976
+371
+23% +$80.2K ﹤0.01% 766
2019
Q2
$418K Hold
1,605
﹤0.01% 709
2019
Q1
$458K Sell
1,605
-115
-7% -$38.2K ﹤0.01% 672
2018
Q4
$559K Buy
1,720
+205
+14% +$71.2K 0.01% 572
2018
Q3
$681K Buy
1,515
+80
+6% +$31.5K 0.01% 575
2018
Q2
$587K Buy
+1,435
New +$520K ﹤0.01% 607

Other funds holding ABMD

Daiwa Securities Group's ABMD Position: Q4 2022 in Review

Daiwa Securities Group sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 3,067 shares — an estimated $753K sold.

Daiwa Securities Group first reported a position in ABMD in Q2 2018 and held it in 18 quarters. The position peaked at $1.02M in Q1 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Daiwa Securities Group reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 3,067 Abiomed Inc shares in Q4 2022, an estimated $753K.
  • Daiwa Securities Group first reported a position in Abiomed Inc in Q2 2018 and held it in 18 quarters.
  • Daiwa Securities Group's Abiomed Inc position peaked at $1.02M in Q1 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.